NEWTOWN, Pa.--(BUSINESS WIRE)--Feb 28, 2012-- BioClinica(R), Inc.
(NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced that Amarin Corporation plc has chosen the eClinical suite from BioClinica to capture and manage clinical data for their Phase IIIb cardiology clinical trial, including: electronic data capture (EDC) and data management, interactive response technology (IRT/IVR/IWR), and clinical trial management (CTMS) solutions. Amarin Corporation is a late-stage biopharmaceutical company focused on the treatment of cardiovascular disease. The study is planned to involve approximately 300 sites and 8,000 patients globally.
BioClinica's Trident IWR and EDC systems were selected based on BioClinica's advanced technology portfolio, experience with large global trials; and cardiology expertise. BioClinica was able to build and deploy the study within 4 weeks.
"We are pleased that Amarin's clinical development team selected an integrated solution from BioClinica that will seamlessly share essential clinical data while streamlining their clinical data and site management processes," said Peter Benton, BioClinica's President of eClinical Solutions. "In the last two quarters we have seen sponsors and CROs significantly increase their interest and investment in solutions that are not only "best-in-class" but also reduce the cost and hassle of unifying their clinical data to both manage their trials as well as readying their data for analysis." Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog, and on twitter at http://twitter.com/bioclinica.
About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.
CONTACT: BioClinica, Inc.
Jim Dorsey, 267-757-3040 or Diccicco Battista Communications Trade Media: Rachel Summers, 484-342-3600 or Porter, LeVay & Rose, Inc.
Investor Contact: Michael Porter Financial Media: Bill Gordon 212-564-4700 KEYWORD: UNITED STATES NORTH AMERICA PENNSYLVANIA INDUSTRY KEYWORD: TECHNOLOGY DATA MANAGEMENT SOFTWARE HEALTH BIOTECHNOLOGY PHARMACEUTICAL SOURCE: BioClinica, Inc.
Copyright Business Wire 2012 PUB: 02/28/2012 08:51 AM/DISC: 02/28/2012 08:51 AM http://www.businesswire.com/news/home/20120228006011/